Display Settings:

Format

Send to:

Choose Destination
Immunology. 2013 Sep;140(1):70-7. doi: 10.1111/imm.12111.

Interleukin-33 exacerbates acute colitis via interleukin-4 in mice.

Author information

  • 1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.

Abstract

Interleukin-33 (IL-33) and its receptor ST2 are over-expressed in clinical colitis tissue. However, the significance of these observations is at present unknown. Significantly, we demonstrate here that IL33 and ST2 are the primary early genes induced in the inflamed colon of BALB/c mice following dextran sulphate sodium (DSS)-induced experimental ulcerative colitis. Accordingly diarrhoea and DSS-induced colon inflammation were impaired in ST2(-/-) BALB/c mice and exacerbated in wild-type mice by treatment with exogenous recombinant IL-33, associated respectively with reduced and enhanced expression of chemokines (CXCL9 and CXCL10), and inflammatory (IL-4, IL-13, IL-1, IL-6, IL-17) and angiogenic (vascular endothelial growth factor) cytokines in vivo. The exacerbation effect of treatment with recombinant IL-33 on DSS-induced acute colitis was abolished in IL-4(-/-) BALB/c mice. Hence, IL-33 signalling via ST2, by inducing an IL-4-dependent immune response, may be a major pathogenic factor in the exacerbation of ulcerative colitis.

© 2013 John Wiley & Sons Ltd.

KEYWORDS:

ST2 deficiency; colitis; early interleukin-33 expression; interleukin-4 deficiency

PMID:
23582173
[PubMed - indexed for MEDLINE]
PMCID:
PMC3809707
[Available on 2014/9/1]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Blackwell Publishing
    Loading ...
    Write to the Help Desk